Search Patents
  • Patent number: 12115150
    Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Grant
    Filed: August 31, 2022
    Date of Patent: October 15, 2024
    Assignee: RedHill Biopharma Ltd.
    Inventors: Dror Ben-Asher, Reza Fathi, Mark Levitt, Ofra Barnett
  • Publication number: 20220184053
    Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Application
    Filed: December 15, 2021
    Publication date: June 16, 2022
    Inventors: Dror Ben-Asher, Reza Fathi
  • Publication number: 20220031682
    Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Application
    Filed: October 15, 2021
    Publication date: February 3, 2022
    Inventors: Dror Ben-Asher, Reza Fathi
  • Patent number: 11052073
    Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: July 6, 2021
    Assignee: RedHill Biopharma Ltd.
    Inventors: Dror Ben-Asher, Reza Fathi
  • Publication number: 20230000845
    Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Application
    Filed: August 31, 2022
    Publication date: January 5, 2023
    Inventors: Dror Ben-Asher, Reza Fathi, Mark Levitt, Ofra Barnett
  • Patent number: 11498944
    Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).
    Type: Grant
    Filed: January 30, 2021
    Date of Patent: November 15, 2022
    Assignees: Janssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Mark Johannes Gerardus Bakkers, Rinke Bos, Frank Wegmann, David Adrianus Theodorus Maria Zuijdgeest, Dan H. Barouch, An Vandebosch, Mathieu Claude Michel Le Gars, Jerald C. Sadoff
  • Patent number: 11384122
    Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: July 12, 2022
    Assignees: Janssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Mark Johannes Gerardus Bakkers, Rinke Bos, Frank Wegmann, David Adrianus Theodorus Maria Zuijdgeest, Dan H. Barouch, An Vandebosch, Mathieu Claude Michel le Gars, Jerald C. Sadoff
  • Publication number: 20210246170
    Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).
    Type: Application
    Filed: January 30, 2021
    Publication date: August 12, 2021
    Inventors: Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Mark Johannes Gerardus BAKKERS, Rinke BOS, Frank WEGMANN, David Adrianus Theodorus Maria ZUIJDGEEST, Dan H. BAROUCH, An VANDEBOSCH, Mathieu Claude Michel le GARS, Jerald C. SADOFF
  • Publication number: 20210388032
    Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).
    Type: Application
    Filed: July 28, 2021
    Publication date: December 16, 2021
    Inventors: Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Mark Johannes Gerardus BAKKERS, Rinke BOS, Frank WEGMANN, David Adrianus Thedorus Maria ZUIJDGEEST, Dan H. BAROUCH, An VANDEBOSCH, Mathieu Claude Michel le GARS, Jerald C. SADOFF
  • Publication number: 20230075527
    Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).
    Type: Application
    Filed: January 30, 2021
    Publication date: March 9, 2023
    Inventors: Dan H. BAROUCH, Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Mark Johannes Gerardus BAKKERS, Rinke BOS, Frank WEGMANN, David Adrianus Theodorus Maria ZUIJDGEEST, An VANDEBOSCH, Mathieu Claude Michel LE GARS, Jerald C. SADOFF
  • Publication number: 20220323533
    Abstract: The present disclosure relates to a composition for preventing, inhibiting or treating coronavirus infection, including an effective amount of camellia saponin. The camellia saponin may be extracted from oil press cake of camellia, and the coronavirus may be severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The composition according to the present disclosure can effectively prevent or inhibit or treat the coronavirus infection by inhibiting the activity of coronavirus without side effects. In addition, the composition according to the present disclosure can inhibit the penetration of the coronavirus into the human body by eliminating the coronavirus remaining on the skin.
    Type: Application
    Filed: April 6, 2022
    Publication date: October 13, 2022
    Applicant: AMOREPACIFIC CORPORATION
    Inventors: Hyunjung CHOI, Jaeyoung KO, Yonghee LEE, Hyoung June KIM, Wonseok PARK, Heungsoo BAEK
  • Publication number: 20230117744
    Abstract: The present disclosure provides compositions, for example vaccine compositions comprising live, attenuated coronavirus. The disclosure also provides methods of using coronavirus vaccines, including methods of treating and/or preventing coronavirus infections, and provides methods of preparing coronavirus vaccines.
    Type: Application
    Filed: March 23, 2021
    Publication date: April 20, 2023
    Inventors: Susan Baker, Xufang Deng, Kelly Milton Lager, Kay Faaberg, Alexandra DeVries
  • Publication number: 20230095701
    Abstract: Use of albiflorin or a pharmaceutically acceptable salt thereof or an extract or a pharmaceutical composition containing albiflorin in the preparation of a medicament for preventing or treating coronavirus pneumonia, especially novel coronavirus pneumonia, or use thereof in the preparation of a medicament for treating prolonged symptoms of novel coronavirus pneumonia, performing rehabilitation conditioning after recovery of novel coronavirus pneumonia, or alleviating a possible sequela of novel coronavirus pneumonia, the sequela being depression, anxiety, sleep disorder, pain, palpitation, asthma, intestinal function disorder, or chronic fatigue syndrome. Albiflorin has the effects of anti-coronavirus, anti-inflammatory, inflammatory storm inhibition, human microecological balance regulation, etc.
    Type: Application
    Filed: September 25, 2020
    Publication date: March 30, 2023
    Inventor: Zuoguang Zhang
  • Publication number: 20230158124
    Abstract: A drug, food and application of an anti-coronavirus infection, the drug or food containing lysozyme or a combination that comprises lysozyme; the lysozyme or a combination thereof can be used to prepare a drug for anti coronavirus infection and preventing or treating coronavirus-related diseases or symptoms, or food for assisting in anti coronavirus infection and assisting in preventing or treating coronavirus-related diseases or symptoms. The present disclosure has a good preventive and therapeutic effect on coronavirus infection or related diseases or symptoms thereof; in addition, the present application can accelerate the elimination of the virus in vivo, accelerate the speed of coronavirus nucleic acid tests in vivo turning negative, shorten the course of a patient's illness, effectively prevent and reduce the spread of coronavirus, and also has important social benefits and good application prospects.
    Type: Application
    Filed: December 4, 2020
    Publication date: May 25, 2023
    Applicants: GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD, GUANGZHOU XIN-CHUANGYI BIOPHARMACEUTICAL CO., LTD, GUANGZHOU XIN CHUANG YI CO., LTD, XIANGBEI WELMAN PHARMACEUTICAL CO., LTD, NANJING KANGFUSHUN PHARMACEUTICAL CO., LTD
    Inventors: Mingjie SUN, Tianyu SUN, Changqing LI
  • Publication number: 20160339097
    Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition.
    Type: Application
    Filed: August 4, 2016
    Publication date: November 24, 2016
    Applicant: MJ Biologics, Inc.
    Inventor: Byoung-Kwan Kim
  • Publication number: 20250057819
    Abstract: A combination comprising tilorone/nelfinavir; tilorone/molnupinavir; tilorone/remdesivir; tilorone/alfacalcidol: tilorone/clofazimine; tilorone/danazol; tilorone/manidipine; tilorone/sertraline; tilorone/trifluoperazine; remdesivir/hexachlorophene; remdesivir/mycophenolate; mycophenolate/hexachlorophene; mycophenolate/nelfinavir; or mycophenolate/nitazoxanide. This combination can be used for blocking the replication of a coronavirus in a coronavirus-infected cell, for treating an infection by a coronavirus in a subject, for treating a coronavirus-related disease in a subject, and/or for reducing the risk of developing a coronavirus-related disease or the severity of a coronavirus-related disease in a subject.
    Type: Application
    Filed: December 22, 2022
    Publication date: February 20, 2025
    Inventors: Steven LAPLANTE, Richard Boulon, Clément Mazeaud, Alain Lamarre, Laurent Chatel-Chaix
  • Publication number: 20230149534
    Abstract: The disclosure provides an immunogenic composition comprising an haptenized Spike protein (S protein) or fragment thereof from a coronavirus and at least one pharmaceutically acceptable carrier, wherein the coronavirus comprising severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Further disclosed are methods of using the haptenized S proteins from coronavirus or immunizing a subject against coronavirus infection.
    Type: Application
    Filed: March 19, 2021
    Publication date: May 18, 2023
    Inventors: David Berd, James Passin
  • Publication number: 20210236497
    Abstract: Disclosed herein are methods, formulations, and kits for treating coronavirus infections, including Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections. Further disclosed are stop-gap methods for controlling the spread of coronavirus infections and the emergence of drug resistant strains of coronavirus.
    Type: Application
    Filed: April 16, 2020
    Publication date: August 5, 2021
    Applicant: OYAGEN, INC.
    Inventors: Harold C. SMITH, Ryan P. BENNETT
  • Publication number: 20210338708
    Abstract: The present invention involves a novel method for treatment of coronavirus infection, including SARS-COV-2. The method comprises administering stannous protoporphyrin and/or cyanocobalamin to a human patient at risk for developing complications from coronavirus infection. The method is particularly useful where a patient has been diagnosed with coronavirus infection or has been exposed to coronavirus but has not developed symptoms of coronavirus infection.
    Type: Application
    Filed: March 18, 2021
    Publication date: November 4, 2021
    Inventors: Donald Jeffrey KEYSER, Alvaro F. GUILLEM, Bhupinder SINGH, Richard A. ZAGER, Stacey RUIZ
  • Publication number: 20060286124
    Abstract: The present disclosure relates to compositions and methods for treating or preventing coronavirus infections. For example, compositions are provided that comprise a coronavirus S protein or N protein, fragment, or variant thereof, capable of eliciting a protective humoral and/or cell-mediated immune response, which compositions are useful for treating or preventing infection by coronavirus, such as the causative agent of SARS. Also, coronavirus S protein and N protein immunogen compositions are provided that include an adjuvant, such as Proteosome or Protollin, which may be used for treating or preventing infection caused by a coronavirus, such as a SARS coronavirus.
    Type: Application
    Filed: June 30, 2005
    Publication date: December 21, 2006
    Applicant: ID Biomedical Corporation of Quebec
    Inventors: David Burt, Mark Reddish, Mary Hu, George Lowell, David Jones
Narrow Results

Filter by US Classification